Theme: Recent Innovations in Neuropharmacological StudiesRecent Innovations in Neuropharmacological Studies

Neuropharmacology 2016

Renowned Speakers

Neuropharmacology 2016

Scientific Program Day 1 | Scientific Program Day 2 | Scientific Program Day 3

Conference Series LLC Conferences invites all the participants from all over the world to attend "4th Global Experts Meeting on Neuropharmacology" during September 14-16, 2016 in San Antonio, USA which includes prompt Keynote Presentations, Oral talks, Poster presentations and Exhibitions.

Neuropharmacology 2016 is the learning of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behavior. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more. Conference Series LLC organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Neuro Immune Pharmacology

It deals with a branch of immunology concerned with the interactions between immunological and nervous system functions also associated autoimmune diseases.  Cortical system involves the study of mapping neural systems associated in the processing of emotion, and it focuses on the cortical components of the process of recognizing facial expressions. Encephalitis is acute inflammation of the brain resulting from a viral infection or an autoimmune disease. Transverse myelitis is a pathogenetically heterogeneous inflammatory disorder in which spinal cord is affected. Huntington disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.

Blood brain barrier is a selectively permeable membrane that separates the blood in the brain from other extracellular fluids. Meningitis, epilepsy, cerebral edema, multiple sclerosis etc. are various diseases associated with it. The children of age group 1 to 14 are more prone to cancer, out of which 18% is the case of brain tumour. In the first three decades of life, central nervous system has emerged as one of the three vulnerable leading sites for cancer mortality. Cerebral lymphoma is the most rapidly increasing brain tumour. 

Related Conferences: 2nd Neuroimmunology and Therapeutics Congress, December 01-03 2016, USA; 5th World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference March 27-29, 2017, USA; European Neurology Congress, September 10-12, 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 2: Molecular Neuropharmacology

Molecular neuropharmacology involves the study of neurons and agonist, Competitive antagonist and Non-competitive antagonist, receptors on neurons for developing new drugs that will treat neurological disorders of neurodegenerative diseases. Neurogenesis and repair refers to the growth and development of neuron. Neurons never function in isolation; they are organized into ensembles or circuits that process kinds of information which are referred as neuronal circuits. The GABA inhibitory neurotransmitter and serotonin neurotransmitter present in the central nervous system of mature vertebrate interacts with GABA receptor and 5HT receptor respectively. GABAA receptors are modulated by the channel of 5HT receptors through activation of various proteins. There are about 14 5HT receptor subtypes identified from last 20 years which are now researched for their significance in various disorders and treatments. Synaptopathy is a progressively popular term used to define main features of psychiatric and neurodegenerative diseases. It infers that brain diseases are resulted from disruption of synaptic structure and function.

Related Conferences: Conference on Pediatric Neurology, November 28-30, 2016 Valencia, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference March 24-29 2017, USA; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration ConferenceApril 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016, Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 3: Clinical Neuropharmacology

It is the science that studies the features, properties, responses and uses of drugs mainly their therapeutic effect in humans along with toxicology, pharmacodynamics and pharmacokinetics. It also includes drug abuse, pain and hypothalamic releasing factors. 

Related Conferences: Conference on Pediatric Neurology, November 28-30, 2016 Valencia, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting, November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 4: Psychopharmacology

Psychopharmacology is the learning of the effects of medication on the psyche (psychology), observing changed behaviors and how molecular events are manifest in a measurable behavioral form. Neurogenesis and repair deal with other aspects on the indications for medications prescribed to address psychiatric and behavioral problems, that are associated with, including antipsychotic, anxiolytic and anticonvulsant medications, acquired brain injury and psychopharmacology drugs and their interaction with neurotransmitters also include mood stabilizers and treatments prescribed for disorders of attention. The treatments may cause side effects such as induction of the metabolic syndrome, type II diabetes related to the medications prescribed for management of psychiatric and behavioural disorders and disturbances. The effectiveness of the drugs can be increased by prescriber’s knowledge over emotional and interpersonal issues of the patient i.e. psychology of psychopharmacology. Schizophrenia is such a disorder which affects the thinking and acting ability of a person caused by viral infection, genetically or by immune disorder.   

Related Conferences: 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; UK; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference, March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting, November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna; 47th Annual Autism Society National Conference, July 13-16 2016, USA, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 5: Neurochemical Transmission and its Associated Interactions

Neurochemistry is the specific study of neurochemicals, including neurotransmitters and other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters that influence the function of neurons. It also deals how these neurochemicals influence the network of neural operation. The studies include micro-macro connection between the analysis of organic compounds active in the nervous system and neural processes such as cortical plasticity, neurogenesis and neural differentiation, synapses, autism and intellectual disability, interneuronal coordination, interaction of drugs and its effect on summation and cotransmission process and advances in astrocyte-neuron interactions in health. Astrocyte dysfunction results into neurodegenerative diseases, stroke, epilepsy, migraine and neuroinflammatory diseases.

Related Conferences: 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; 5th World Neurology and Therapeutics Congress, March 27-29 2017, Spain; 3rd World Pharmacology Congress, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 6: Behavioral Neuropharmacology

It is the study of drug dependence and how drug addiction affects the human mind, Anxiety and Autism, Measuring neural activity in Drug abuse, Alcoholism- tolerance to and physical dependence, and properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens, Post-traumatic stress disorder and borderline personality disorder, clinical depression and enhanced treatments.

Related Conferences: International Pediatric Neurology Conference, November 28-30, 2016 Valencia, Spain, October 10-12, 2016, Spain; 5th World Congress on Neurology and Therapeutics, March 27-29 2017, Spain; 3rd World Pharmacology Conference, August 08-10, 2016, UK; 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016, Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy; 47th Annual Autism Society National Conference, July 13-16, 2016, USA, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 7: Chemical Neurotrasmitters

These are the brain chemicals that connect brain and the body.  They transmit signals between nerve cells, called neurons. They can also affect mood, sleep, concentration, weight, and can cause adverse symptoms when they are out of balance. These are of two types: Inhibitory and Excitatory. Acetylcholine, Glutamine and GABA are some of these neurotransmitters.

Related Conferences: International Pediatric Neurology Conference, November 28-30, 2016 Valencia, Spain, October 10-12, 2016, Spain; 5th World Congress on Neurology and Therapeutics, March 27-29, 2017, Spain; 3rd World Pharmacology Conference, August 08-10, 2016, UK; 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; European Neurology Congress, September 10-12 2016, Amsterdam; Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy; 47th Annual Autism Society National Conference, July 13-16, 2016, USA, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 8: Neurotechnology and its Advances

It is the measurement and analysis of chemical and electrical signals of nervous system. It includes neurocircuitary analysis, novel trans-synaptic tracing approaches, advancements of optical techniques, neuromodulation and transcranial magnetic stimulation. Neurotechnology plays a crucial role in diagnostics and identification of nervous activities.

Related Conferences: 2nd Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology and Therapeutics, March 27-29 2017, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Pharmacology and Ethnopharmacology Conference, March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna;  47th Annual Autism Society National Conference, July 13-16 2016, USA, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 9: Neuroendocrinology

It is the study of interactions between the nervous system and the endocrine system, also biological features of the cells involved and their communications. Most Important aspects of neuroendocrinology are insulin receptor and hypothalamic programming; stress, coping and interactions, neuro-endocrine-immune symphony, pituitary structure and hormone secretion.

Related Conferences: International Pediatric Neurology Conference, November 28-30, 2016 Valencia, Spain, October 10-12, 2016, Spain; 5th World Neurology and Therapeutics Conference, March 27-29 2017, Spain; 3rd World Pharmacology Conference, August 08-10, 2016, UK; 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy.47th Annual Autism Society National Conference, July 13-16, 2016, USA, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 10: Alzheimer's Disease and Dementia

Alzheimer's is a type of dementia that causes problems with memory, thinking and behaviour. Symptoms usually develop slowly and become severe enough to interfere with daily tasks. Amyloid plaques are also found in the brain of Alzheimer patients. Neurocognitive effects associated with therapeutic drugs and animal cognition and behaviour - Fear and aversive learning and memory.

Related Conferences: 5th International Alzheimer’s Disease & Dementia Conference, September 29-October 01, 2016, UK; 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; 5th World Neurology and Therapeutics Conference, March 27-29 2017, Spain; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy.47th Annual Autism Society National Conference, July 13-16, 2016, USA, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 11: Parkinson’s Disease

It is a progressive and chronic disorder, caused by death or malfunctioning of neurons, genetic mutation leading to decreased level of dopamine secretion. Associated effects are anxiety; depression, stress, ageing and neurodegenerative disorders, disease diagnostics, drug designing and therapeutics are the research areas.

Related Conferences:  2nd Conference on Parkinson’s Disease & Movement Disorders November 28-30 2016, USA; 2nd Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology and Therapeutics, March 27-29 2017, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Neuro-Oncology Conference, July 21-23 2016, Australia; Alzheimer’s Association International Conference, July 22-28 2016, Canada; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016, Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna; Schizophrenia International Research Society Conference, April 2-6 2016, Italy. Schizophrenia International Research Society Conference, April 4-8 2018, Italy, National Institute of Neurological Disorders and StrokeAustralian Neuroscience SocietyThe American Clinical Neurophysiology SocietyInternational Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 12: Neuroethics

It includes the social, legal and ethical consequences of advances in neuroscience. It is the amalgamation of neuroscience with ethical thoughts. The ethics of neurocognitive includes brain interventions and imagining, neurological treatments and consciousness disorders. 

Related Conferences: Conference on Pediatric Neurology, November 28-30, 2016 Valencia, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 13: Future Aspects of Neuropharmacology

Neuropharmacology is an emerging field of science, rising exponentially with the understanding of nervous system and its related disorders, drugs and treatments. The major area of research includes mechanisms of novel drugs, neuro stem cell therapy, immunoglobulin therapy, gene therapy in neuronal disorders and neural engineering. 

Related Conferences:  5th International Alzheimer’s Disease & Dementia Conference, September 29-October 01, 2016, UK; 2nd Epilepsy & Treatment Conference, October 24-26 2016, Italy; 5th World Neurology and Therapeutics Conference, March 27-29 2017, Spain; European Neurology Congress, September 10-12 2016, Amsterdam; International Neuro-Oncology Conference, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration Conference April 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy; 47th Annual Autism Society National Conference, July 13-16, 2016, USA, National Institute of Neurological Disorders and Stroke, Australian Neuroscience Society, The American Clinical Neurophysiology Society, International Society of Neuropathology (ISN), International Society of Psychoneuroendocrinology (ISPNE)

Track 14: Case Study Reports

Case studies are an extremely useful records of the clinical practices of a profession. They are a record of clinical interactions which help us to frame questions for more rigorously designed clinical studies. Case studies also provide valuable teaching material, demonstrating both classical and unusual presentations which may challenge the practitioner.

Related Conferences:  Conference on Pediatric Neurology, November 28-30, 2016 Valencia, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology March 27-29, 2017 USA; European Neurology Congress, September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Proteostasis & Neurodegeneration ConferenceApril 01-04 2017, Vietnam; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17, 2016, USA; Schizophrenia International Research Society Conference, April 4-8 2018, Italy, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN), American Neurological Association (ANA), American Society of Neuroimaging, European Federation of Neurological Societies

Track 15: Entrepreneurs Investment Meet

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.

Conference Series LLC  invites all the participants from all over the world to attend '4th Global Experts Meeting on Neuropharmacology' during September 14-16, 2016 in San Antonio, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Neuropharmacology  2016 is the learning of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behavior. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including  neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more. Conference Series LLC organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about neuropharmacology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Neuropharmacology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Neuropharmacology are hallmarks of this conference.

Target Audience:

  • Neuropharmacology Students, Scientists
  • Neuropharmacology Researchers
  • Neuropharmacology Faculty
  • Medical Colleges
  • Neuropharmacology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies

Summary: Neuropharmacology 2016 welcomes attendees, presenters, and exhibitors from all over the world to San Antonio, USA. We are delighted to invite you all to attend and register for the “4th Global Experts Meeting on Neuropharmacology (Neuropharmacology 2016)” which is going to be held during September 14-16, 2016 at San Antonio, USA. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Neuropharmacology-2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Neuropharmacology 2016 organizing committee look forward to meet you at San Antonio, USA.

For more details please visit- http://neuro.pharmaceuticalconferences.com/

Importance and Scope:  Neuropharmacology is the study of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behaviour. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more.

It is necessary to focus on neuropharmacology and the use of neuropharmaceuticals to transform brain processes in the way of enhancing memory, mood, sensation, thinking and attention in people.

Comparative analysis for Neurological Disorders (Age wise profile)

Why San Antonio, USA?

The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018. The United States is the world’s largest market for pharmaceuticals and the world leader in biopharmaceutical research. The biopharmaceutical pipeline also has over 5,000 new medicines currently in development around the world with approximately 3,400 compounds currently being studied in the United States. San Antonio itself is a home of many pharmaceutical companies such as BioNumerik Pharmaceuticals, Evestra, Genemed synthesis, GenSpera, Genzyme, Ockham Development Group, Radiant Research, SRI International and universities like University of Texas. San Antonio is also a famous tourist destination. The major attraction includes Spanish colonial missions, the Alamo, the River Walk, the Tower of the Americas, the Alamo Bowl, and Marriage Island.

Conference Highlights

  • Neuro immune pharmacology and its associated diseases
  • Molecular Neuropharmacology
  • Psychology of Psychopharmacology
  • Neurochemical transmission and its associated interactions
  • Behavioral neuropharmacology
  • Neurotechnology and its advances
  • Alzheimer’s disease and dimentia
  • Parkinson’s disease
  • Neuroethics
  • Neuroscience
  • Neuroendocrinology
  • Future Aspects of Neuropharmacology 

Attendance Profile according to specialization in a Neuroscience Conference

Members associated with Neuropharmacology

  

Hospitals of Neuropharmacology

Top Hospitals in USA

  • Mayo Clinic, Rochester, Minnesota
  • Johns Hopkins Hospital, Baltimore, Maryland
  • Massachusetts General Hospital, Boston
  • University of California–San Francisco Medical Center
  • Mathodist Hospital, San Antonio
  • University of California–Los Angeles Medical Center
  • New York University Langone Medical Center, New York City
  • Hospitals of the University of Pennsylvania–Penn Presbyterian
  • Northwestern Memorial Hospital, Chicago
  • Baptist Medical Centre, San Antonio

Major Neuropharmacology related Associations around the Globe

  • Canadian Neurological Sciences Federation
  • European Parkinson’s disease Association
  • Malaysian Society of Neurosciences
  • Eurospine, The Spine Society Of Europe
  • The Spanish Society of Neurology (SEN)
  • The Czech Neuropsychopharmacological Society
  • Belgian Neurological Society
  • National Neurotrauma Society 
  • National Parkinson'S Foundation
  • European Society Of Neurosonology And Cerebral Hemodynamics
  • Federation Of European Neuroscience Societies
  • Malaysian Society Of Neurosciences
  • Česká Neurologická Společnost
  • The Czech Neuropsychopharmacological Society
  • European Academy Of Neurology
  • Deutsche Gesellschaft Fur Neurologieologie 
  • International Brain Research Organization
  • The Neuropathy Association
  • The Primary Care Neurology Society
  • The Spanish Society Of Neurology (SEN)

Major Neuropharmacology related Associations in USA

  • International Neuroethics Society
  • Society for Behavioral Neuroendocrinology
  •  Society For Neuroscience
  • American Psychological Association
  • International Parkinson and Movement Disorder Society
  • American Neurological Association
  • National Institute Of Environmental Health Sciences
  • The American Society of Neuroimaging
  • American Board Of Psychiatry And Neurology, Inc.
  • American Clinical Neurophysiology Society
  • International Neuropsychological Society
  • Southern Clinical Neurological Society
  • International Parkinson And Movement Disorder Society

Major Neuropharmacology related Associations in San Antonio, Texas

  • International Behavioral Neuroscience Society
  • University Health System

Universities in USA

  • Stanford University
  • University of North Carolina—​Chapel Hill
  • University of Minnesota
  • University of Kentucky
  • University of Washington
  • University of Texas
  • University of California
  • University of Maryland
  • Trinity University
  • Texas Southern University
  • University of Houston

   

Products for Neurological Treatments

This above statistic displays the global revenue of Abilify from Bristol-Myers Squibb from 2011 to 2014. In the United States alone, Abilify generated a revenue of 2.1 million U.S. dollars in 2012. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.

Gross Profit Margin of Neuropharmaceutical related companies

Market Capitalization of Neuropharmaceutical companies: In 2014, investors provided $3.3 billion into firms that are developing drugs for brain-destroying or psychiatric illnesses. Some big drug companies, including Johnson & Johnson, Roche and Novartis, are finding ways to reinvigorate their efforts. New medicines for severe depression, psychosis and schizophrenia could reach the market within the next few years, and treatments for Alzheimer’s, Parkinson’s and some forms of autism are a real possibility, too.

Sales Profile of Neuropharmaceutical companies

Research Fund: NIH (National Institute of Health) and NSFC (Nature Science Foundation of China) provided fund for the neurological disorders such as dementia, schizophrenia, stroke, parkinson’s, epilepsy.

Institutes funding for research

1)      The US National Institutes of Health fund a Neuropharmacology Laboratory project, Universitat Pompeu Fabra, Barcelona

2)      Neuropharmacology Program, The National Institute of Mental Health (NIMH)

3)      McKnight Endowment Fund for Neuroscience

  • The statistic depicts the research and development expenditure of the entire pharmaceutical industry of the United States from 1995 to 2014. In 2004, the expenditure of the entire U.S. pharmaceutical industry on research and development came to 47.6 billion U.S. dollars.

Welcome Message

by

Dr. Hari S Sharma

Congress-Chairman

 

On behalf of the Organizing Committee, I have immense pleasure to note that the Conference Series LLC is organizing the 4th Global Experts Meeting on Neuropharmacology, Sep 14-16, 2016 in beautiful city of San Antonio, TX, USA.

”Neuropharmacology” discipline is one of the fundamental aspects of drug discovery and therapy for neurological diseases of diverse origin e.g., from psychological, traumatic to neurodegenerative diseases. Thus, an International Meeting Organized by Conference Series LLC will help develop novel aspects of drug development and future therapeutic strategies for treating neurological diseases that are the need of the hour for clinicians, policy makers, researchers and students alike.

I strongly feel that the continued initiatives of Conference Series LLC for the betterment of mankind by organizing such scientific conferences will be extremely helpful for future research and clinical practices in general and in neurological diseases in particular. Neurological diseases affecting Worldwide e.g., Alzheimer’s Disease, Parkinson’s’ Disease, Huntington’s Disease, Stroke, Dementia, Brain and spinal cord trauma and related psychosomatic diseases affecting central and peripheral nervous system require urgent attention for researchers and clinicians for developing suitable drugs for therapy. This congress is just a novel addition in this field.

The congress is organized in a beautiful, vivid, cultural city of San Antonio that has a history of several hundred years of welcoming people across the Globe. San Antonio is the 7th largest city in the USA and 2nd largest city of Texas in terms of population. The city is attracting more than 26 million tourists World wide every year. I am sure that selecting this city for the congress will add another glamor for social, cultural and touristic attraction while deliberating scientific presentation in a warm nice ambience.

I hope this 3-days scientific discussion and presentations by leading experts in the World as well as new research carried out by young scientist will provide a perfect amalgam for novel drug discovery in both basic and clinical research. The outcome of the congress will pave ways to new developments for drug therapy and raises hope in the victims of neurological disease Worldwide.

I am sure that the delegates, experts, students, researchers, Pharma industries, policy makers and healthcare givers will all tremendously benefit from the deliberation of this congress in a warm and friendly environment.

Your presence and deliberation will make this congress remarkably successful in all aspects of neuropharmacology.


Hari S Sharma, Ph. D., Dr. Med. Sci., FAIS (New York), FABRI (N. Carolina)
Director, Int. Expt. CNS Injury & Repair;
Prof. Neurobiology (MRC)
University Hospital, Uppsala University, Sweden

 

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date September 14-16, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View

Media Partners